pharma · cystic fibrosis · Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
Théa Pharma Ireland
Verona Pharma Ireland Limited
Théa Pharma Ireland clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Castlebar, IE
- Founded
- 2018
- Employees
- 19
- Programs
- 11
- Drugs
- 42
- Patents
- 0
Théa Pharma Ireland projects
4 ClinicalTrials.gov programs sponsored by Théa Pharma Ireland.
Théa Pharma Ireland has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
DISCARD
Verona Pharma Ireland Limited
Patients with currently remitted depressive disorders.
1 trial -
GR-2021-12373041
Verona Pharma Ireland Limited
patients with secondary progressive MS
1 trial -
SIPO20
Verona Pharma Ireland Limited
Active progressive multiple sclerosis course after an initial relapse clinical course
1 trial -
Zeposia 0.92 mg hard capsules
Verona Pharma Ireland Limited
Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
1 trial
Frequently asked questions
How many clinical projects does Théa Pharma Ireland have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.